Three‐year clinical outcomes with the ABSORB bioresorbable vascular scaffold in real life: Insights from the France ABSORB registry. Issue 3 (19th November 2020)

• Record Type: Journal Article
• Authors: Lhermusier, Thibault; Carrie, Didier; Cayla, Guillaume; Fajadet, Jean; Sainsous, Joel; Elhadad, Simon; Tarragano, Francois; Chevalier, Bernard; Ranc, Sylvain; Curinier, Corentin; Le Breton, Herve; Koning, Rene
• Is Part Of: Catheterization and cardiovascular interventions. Volume 98:Issue 3(2021)
• Page Start: 511
• Page End: 519
• Publication Date: 2020-11-19
• Subjects: bioresorbable scaffold -- coronary artery disease -- drug eluting stents -- percutaneous coronary intervention; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.29369
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: The aim of this study was to determine the 3‐year outcomes of patients treated with Absorb bioresorbable vascular scaffold (BVS) implantation. Background: Randomized trials and observational registries performed in patients undergoing percutaneous coronary intervention have demonstrated higher 1‐year and midterm rates of device thrombosis and adverse events with BVS compared to contemporary drug eluting stent. Data on long‐term follow‐up of patients treated with BVS are scarce. Methods: All patients treated with BVS were included in a large nationwide prospective multicenter registry (FRANCE ABSORB). The primary endpoint was a composite of cardiovascular death, myocardial infarction, and target lesion revascularization at 3 years. Secondary endpoints were 3‐year scaffold thrombosis and target vessel revascularization (TVR). Results: Between September 2014 and April 2016, 2070 patients were included (mean age 55 ± 11 years; 80% men). The indication was acute coronary syndrome (ACS) in 49% of patients. At 3 years, the primary endpoint occurred in 184 patients (8.9%) and 3‐year mortality in 43 patients (2.1%). Scaffold thrombosis and TVR rates through 3 years were, respectively, 3 and 7.6%. In a multivariable analysis, independent predictors of primary endpoint occurrence were diabetes, oral anticoagulation, active smoking, absence of initial angiographic success and the association of a total BVS length ≥30 mm with the use of 2.5 mm diameter BVS. Conclusions: Although 3‐year mortality was low in this ACS population, device‐related events were significant beyond 1 year. Total BVS length and 2.5 mm BVS were associated with higher rates of MACE at long‐term follow‐up.